文献速递糖尿病

格列美脲联合或单用利格列汀治疗HNF1A糖尿病(青少年发病的成人型糖尿病3型)的疗效与安全性:一项随机、双盲、安慰剂对照交叉试验(GLIMLINA)

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
PubMed 文献 · Diabetes Care · 2020-07-13

这项随机双盲交叉试验纳入19例HNF1A糖尿病患者,比较格列美脲联合利格列汀5 mg与格列美脲联合安慰剂治疗各16周。联合治疗未显著改善主要终点血糖波动平均幅度,但显著降低血糖变异系数、糖化血红蛋白和格列美脲剂量,低血糖发生率相似。

要点

  • 格列美脲联合利格列汀未显著改善主要终点MAGE(平均差-0.7 mmol/L,P=0.1540)。
  • 联合治疗显著降低CGM血糖变异系数(-3.6%,P=0.0401)和HbA1c(-0.5%,P=0.0048)。
  • 联合治疗显著降低格列美脲剂量(-0.7 mg/天,P=0.0099),低血糖发生率相似。

核心结论

  • 在HNF1A糖尿病患者中,利格列汀作为格列美脲的添加治疗改善了血糖变异性和血糖控制,且未增加低血糖风险。

研究设计与样本

  • 随机、双盲、交叉试验纳入19例HNF1A糖尿病患者,平均±标准差年龄43±14岁,BMI 24.8±2.8 kg/m2,糖化血红蛋白7.4±0.2%(57.1±7.3 mmol/mol)。
  • 患者随机接受格列美脲+利格列汀5 mg治疗16周、洗脱4周、格列美脲+安慰剂治疗16周(或相反顺序)。
  • 格列美脲滴定目标为空腹血浆葡萄糖4.5-6.0 mmol/L且无低血糖。
  • 通过连续血糖监测(CGM)、糖化血红蛋白和餐试验评估治疗。

主要发现

  • 与格列美脲+安慰剂相比,格列美脲+利格列汀未显著改善主要终点血糖波动平均幅度(MAGE)(平均差-0.7 mmol/L,P=0.1540)。
  • 格列美脲+利格列汀较格列美脲+安慰剂显著降低CGM血糖变异系数(-3.6%,P=0.0401)。
  • 格列美脲+利格列汀较格列美脲+安慰剂显著降低糖化血红蛋白(-0.5%,P=0.0048)。
  • 格列美脲+利格列汀较格列美脲+安慰剂显著降低格列美脲剂量(-0.7 mg/天,P=0.0099)。
  • 餐试验中β细胞葡萄糖敏感性(以C肽与葡萄糖比值评估)在格列美脲+利格列汀治疗下改善,两种治疗低血糖发生率相似。

临床怎么用

  • 原文结论认为,在HNF1A糖尿病患者中,利格列汀作为格列美脲的添加治疗改善了血糖变异性和血糖控制,且未增加低血糖风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sulfonylureas are first-line treatment of hepatocyte nuclear factor 1-α (HNF1A) diabetes (maturity-onset diabetes of the young type 3), but many patients do not achieve optimal glycemic control without episodes of hypoglycemia. We investigated the combination of the sulfonylurea glimepiride and the dipeptidyl peptidase 4 inhibitor linagliptin versus glimepiride monotherapy with respect to glycemic variability, glycemic control, and risk of hypoglycemia. RESEARCH DESIGN AND METHODS: In a randomized, double-blinded, crossover trial, patients with HNF1A diabetes (n = 19; mean ± SD age 43 ± 14 years, BMI 24.8 ± 2.8 kg/m2, and glycated hemoglobin [HbA1c] 7.4 ± 0.2% [57.1 ± 7.3 mmol/mol]) were randomly assigned to treatment with glimepiride + linagliptin 5 mg (16 weeks), washout (4 weeks), and glimepiride + placebo (16 weeks) (or vice versa). Glimepiride was titrated targeting a fasting plasma glucose of 4.5-6.0 mmol/L without hypoglycemia. Treatments were evaluated by continuous glucose monitoring (CGM), HbA1c, and meal test. RESULTS: Compared with glimepiride + placebo, glimepiride + linagliptin did not significantly improve the primary end point, mean amplitude of glycemic excursions (MAGE) (mean difference -0.7 mmol/L, P = 0.1540), but displayed significant reductions in coefficient of variation on CGM (-3.6%, P = 0.0401), HbA1c (-0.5%, P = 0.0048), and glimepiride dose (-0.7 mg/day, P = 0.0099). β-cell glucose sensitivity (assessed as C-peptide-to-glucose ratio) during meal test improved with glimepiride + linagliptin. Incidences of hypoglycemia were similar with both treatments. CONCLUSIONS: Linagliptin as add-on treatment to glimepiride improved glycemic variability and control without increasing risk of hypoglycemia in patients with HNF1A diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Christensen AS, Hædersdal S, Støy J, et al. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). Diabetes Care. 2020. PMID: 32661107. doi:10.2337/dc20-0408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。